Genitourinary Cancers

Latest News

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.
Pembrolizumab Improves DFS Vs Observation in Muscle-Invasive Urothelial Carcinoma

February 8th 2024

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.

Combining pembrolizumab with cabozantinib produces encouraging efficacy in platinum-ineligible patients with advanced urothelial carcinoma, says Rohit K. Jain, MD, MPH.
Pembrolizumab Combo Yields Efficacy in Advanced Urothelial Carcinoma

February 3rd 2024

Benefits with enfortumab vedotin plus pembrolizumab in prespecified patient subgroups with urothelial carcinoma in the EV-302 trial appear to be consistent with outcomes in the overall study population.
Enfortumab Vedotin Combo Improves Outcomes in Urothelial Cancer Subgroups

February 3rd 2024

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.
Olaparib Combo Improves Survival Vs Placebo in Metastatic CRPC

January 28th 2024

Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib

January 27th 2024

More News